Evidence map›Paper›PMID 30941236›Full record

ArticleJournal of breast cancer2019

Prescription Refill Gap of Endocrine Treatment from Electronic Medical Records as a Prognostic Factor in Breast Cancer Patients.

Yura Lee, Yu Rang Park, Ji Sung Lee, Sae Byul Lee, Il Yong Chung, Byung Ho Son, Sei Hyun Ahn, Jong Won Lee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of breast cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. The Hidden Patient Connections: Predicting Hormonal Therapy Medication Discontinuation Using Hypergraph Neural Network on Clinical Communications.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yura LeeDepartment of Biomedical Informatics, Asan Medical Center, Seoul, Korea.ORCID 0000-0003-2048-3727
Yu Rang ParkDepartment of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Korea.ORCID 0000-0002-4210-2094
Ji Sung LeeClinical Research Center, Asan Medical Center, Seoul, Korea.ORCID 0000-0001-5271-8530
Sae Byul LeeDepartment of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID 0000-0002-3370-6937
Il Yong ChungDepartment of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Byung Ho SonDepartment of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Sei Hyun AhnDepartment of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jong Won LeeDepartment of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID 0000-0001-7875-1603

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDiscontinuation of hormone therapy is known to lead to a poorer prognosis in breast cancer patients. We aimed to investigate the prescription gap as a prompt index of medication adherence by using prescription data extracted from patient electronic medical records.

methodsA total of 5,928 patients diagnosed with invasive, non-metastatic breast cancer, who underwent surgery from January 1, 1997 to December 31, 2009, were enrolled retrospectively. The prescription data for 4.5 years of hormonal treatment and breast cancer-related events after treatment completion were analyzed. We examined the characteristics and prognoses of breast cancer in patients with and without a 4-week gap.

resultsPatients with a gap showed a significantly higher risk of breast cancer recurrence, distant metastasis, breast cancer-specific death, and overall death after adjustment (hazard ratio [HR], 1.389; 95% confidence interval [CI], 1.089-1.772; HR, 1.568; 95% CI, 1.158-2.123; HR, 2.108; 95% CI, 1.298-3.423; and HR, 2.102; 95% CI, 1.456-3.034, respectively). When patients were categorized based on gap summation, the lower third (160 days) and fourth (391 days) quartiles showed a significantly higher risk of distant metastasis (HR, 1.758; 95% CI, 1.186-2.606 and HR, 1.844; 95% CI, 1.262-2.693, respectively).

conclusionA gap of > 4 weeks in hormonal treatment has negative effects on breast cancer prognosis, and can hence be used as a sentinel index of higher risk due to treatment non-adherence. Further evaluation is needed to determine whether the gap can be used as a universal index for monitoring the adherence to hormonal treatment.

Indexed as

Breast neoplasmsEstrogen antagonistsMedication adherenceNeoplasm metastasis

Identifiers

PMID30941236
PMCPMC6438827

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.